Physicians Predict COURAGE Will Reduce U.S. Stent Procedures About 5%
This article was originally published in The Gray Sheet
Executive Summary
The highly publicized COURAGE trial will cause a roughly 5% reduction in the number of stent procedures in the United States, according to Dartmouth Medical School's Aaron Kaplan, M.D., and Carl Szot, M.D
You may also be interested in...
Stent Makers, Interventionists Downplay Impact Of BARI 2D Data
There is little debate that BARI 2D trial data unveiled last week affirmed that percutaneous coronary intervention does not extend the lives of patients with type 2 diabetes and stable ischemic heart disease, but stent manufacturers and interventionalists are scratching their heads as to why anybody would be surprised
Stent Makers, Interventionists Downplay Impact Of BARI 2D Data
There is little debate that BARI 2D trial data unveiled last week affirmed that percutaneous coronary intervention does not extend the lives of patients with type 2 diabetes and stable ischemic heart disease, but stent manufacturers and interventionalists are scratching their heads as to why anybody would be surprised
Quality-Of-Life Data Favor Stenting Over Drugs Only In Short-Term
A newly published quality-of-life analysis from the high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease